New York TimesA Cancer Conundrum: Too Many Drug Trials, Too Few Patients …New York TimesBreakthroughs in immunotherapy and a rush to develop profitable new treatments have brought a crush of clinical trials scrambling for patients.and more »… Continue reading
Salon |
Stem cell therapy for heart failure gets a gold-standard trial
Salon One company, Melbourne, Australia–based Mesoblast, is already in late-stage clinical trials, treating hundreds of chronic heart failure patients with stem cell precursors drawn from healthy donors’ hip bones. A randomized trial that includes a placebo … |
Sports Perspectives |
Editas Medicine’s (EDIT) CEO Katrine Bosley on Q2 2017 Results – Earnings Call Transcript
Seeking Alpha Cpf1 is a new CRISPR genome-editing system that substantially expands the range of genomic sites we can target, and it may also have advantages in terms of specificity, manufacturing and delivery. In addition, Cpf1 may enable us to achieve more … Editas Medicine Announces Second Quarter 2017 Results and UpdateNasdaq Editas Medicine, Inc. (NASDAQ:EDIT) Stock Closed 15.5% Above Its 50 Day Moving AverageHugoPress |
|
Students help to save lives through stem cell donations
Falmouth Packet Students at the Penryn Campus are hoping to save lives by donating their stem cells to strangers who are fighting cancer. A campaign set up to help students at the University of Exeter at Tremough to “do good” has resulted in two people working with … |
|
Gene Therapy is Finally Here, But Who Will Foot the Bill
Wall Street Pit Cancer, diabetes, and heart disease are classified as multifactorial inheritance genetic disorders. Considering all these, one would expect that the world will be welcoming the revolutionary gene therapy with wide-open arms. Yet, UniQure’s Glybera has … |
|
USC Stem Cell scientists obtain ‘how to’ guide for producing hair follicles
EurekAlert (press release) In the study, first author Mingxing Lei, a postdoctoral scholar in the USC Stem Cell laboratory of Cheng-Ming Chuong, and an international team of scientists started with dissociated skin cells from a newborn mouse. Lei then took hundreds of timelapse … |
|
REGENXBIO to Present on RGX-314 Gene Therapy Program for Wet AMD at 35th Annual Scientific Meeting of the …
Nasdaq ROCKVILLE, Md., Aug. 11, 2017 (GLOBE NEWSWIRE) — REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology … |